In most instances, we noted a suppression of the three anti-apoptotic Bcl-2 family members in established GBM cells (U87, T98G and U251) following treatment with the combination treatment of gamitrinib and panobinostat as compared to vehicle treatment (Figure 3A and Figure S5A–D). Here, BCL2 is linked to glioblastoma.